Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARQTNASDAQ:ATNXNASDAQ:ENTANASDAQ:RTRXNASDAQ:STOK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$9.10-3.7%$10.01$1.76▼$15.21$880.97M1.144.78 million shs4.52 million shsATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsENTAEnanta Pharmaceuticals$13.32+0.7%$14.80$8.08▼$37.75$281.85M0.47263,023 shs139,418 shsRTRXTravere Therapeutics$5.72-1.4%$26.56$8.98▼$24.96$292.02M0.67412,277 shs946,701 shsSTOKStoke Therapeutics$12.05+3.4%$8.62$3.35▼$16.40$557.92M0.77976,811 shs1.01 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-7.80%-20.45%-4.16%+190.77%-30.46%ATNXAthenex0.00%0.00%0.00%0.00%-86.09%ENTAEnanta Pharmaceuticals-5.50%-21.01%-5.77%+12.98%-64.49%RTRXTravere Therapeutics-3.17%-13.30%-22.46%-33.64%-72.78%STOKStoke Therapeutics-0.60%-13.70%+100.86%+136.31%+29.30%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics1.5416 of 5 stars3.41.00.00.01.92.50.6ATNXAthenexN/AN/AN/AN/AN/AN/AN/AN/AENTAEnanta Pharmaceuticals3.6962 of 5 stars3.10.00.04.73.72.50.6RTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTOKStoke Therapeutics4.1537 of 5 stars4.41.00.04.83.11.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics2.75Moderate Buy$26.56191.82% UpsideATNXAthenexN/AN/AN/AN/AENTAEnanta Pharmaceuticals2.17Hold$19.3345.15% UpsideRTRXTravere TherapeuticsN/AN/AN/AN/ASTOKStoke Therapeutics2.78Moderate Buy$19.6362.86% UpsideCurrent Analyst RatingsLatest ENTA, ARQT, STOK, ATNX, and RTRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/11/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/4/2024STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/26/2024STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $17.003/26/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.003/26/2024STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/26/2024STOKStoke TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/26/2024STOKStoke TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $13.003/26/2024STOKStoke TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.002/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$59.61M14.78N/AN/A$0.94 per share9.68ATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00ENTAEnanta Pharmaceuticals$79.20M3.56N/AN/A$10.29 per share1.29RTRXTravere Therapeutics$175.34M1.67N/AN/A$5.15 per share1.11STOKStoke Therapeutics$8.78M63.54N/AN/A$3.57 per share3.38Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)ATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/AENTAEnanta Pharmaceuticals-$133.82M-$6.56N/AN/AN/A-187.77%-60.38%-32.29%5/13/2024 (Estimated)RTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ASTOKStoke Therapeutics-$104.70M-$2.37N/AN/AN/AN/A-56.86%-41.59%5/2/2024 (Estimated)Latest ENTA, ARQT, STOK, ATNX, and RTRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2024Q4 2023STOKStoke Therapeutics-$0.62-$0.60+$0.02-$0.60$3.70 million$2.80 million2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million 2/7/2024Q1 2024ENTAEnanta Pharmaceuticals-$1.18-$1.58-$0.40-$1.58$22.74 million$18.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AATNXAthenexN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics2.287.086.80ATNXAthenex3.081.090.72ENTAEnanta PharmaceuticalsN/A6.256.25RTRXTravere Therapeutics0.667.237.14STOKStoke TherapeuticsN/A6.996.99OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AATNXAthenex30.48%ENTAEnanta Pharmaceuticals94.99%RTRXTravere TherapeuticsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics20.70%ATNXAthenex9.20%ENTAEnanta Pharmaceuticals13.64%RTRXTravere Therapeutics4.63%STOKStoke Therapeutics12.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics29696.81 million76.77 millionOptionableATNXAthenex6528.66 million7.87 millionOptionableENTAEnanta Pharmaceuticals14521.16 million18.27 millionOptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableSTOKStoke Therapeutics11046.30 million40.61 millionOptionableENTA, ARQT, STOK, ATNX, and RTRX HeadlinesSourceHeadlineStoke-on-Trent to host its first comedy festivalyahoo.com - April 19 at 8:27 AMStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claimsmsn.com - April 19 at 8:27 AMProtest outside Stoke-on-Trent Crown Court - here's whymsn.com - April 19 at 8:27 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stockinsidertrades.com - April 19 at 6:35 AMStoke Therapeutics (NASDAQ:STOK) Trading 4.5% Higher marketbeat.com - April 18 at 2:47 PMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerfinance.yahoo.com - April 17 at 8:40 AMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerbusinesswire.com - April 17 at 8:00 AMBridport 2-0 Stoke Gabriel & Torbay Police: Match reportbridportnews.co.uk - April 17 at 1:25 AMThe focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'msn.com - April 17 at 1:25 AMHow killers planned Stoke DPD worker's 'public execution' before celebrating with blood-soaked weaponsstokesentinel.co.uk - April 17 at 1:25 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Short Interest Updateamericanbankingnews.com - April 13 at 6:58 AMStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - April 13 at 6:16 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Earn Q2 2024 Earnings of ($0.43) Per Shareamericanbankingnews.com - April 13 at 2:16 AMResearch Analysts Offer Predictions for Stoke Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:STOK)americanbankingnews.com - April 13 at 1:44 AMStoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 12 at 9:48 AMQ2 2024 Earnings Forecast for Stoke Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:STOK)marketbeat.com - April 12 at 6:24 AMBuy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioningmarkets.businessinsider.com - April 12 at 12:09 AMStoke Therapeutics' (STOK) Buy Rating Reaffirmed at Needham & Company LLCmarketbeat.com - April 11 at 8:32 AMStoke Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.54) Per Share (NASDAQ:STOK)marketbeat.com - April 11 at 7:26 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 6 at 2:43 AMStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferencebusinesswire.com - April 4 at 4:30 PMStoke Therapeutics (NASDAQ:STOK) Shares Up 5.1%marketbeat.com - April 4 at 2:24 PMAssessing Stoke Therapeutics: Insights From 6 Financial Analystsmarkets.businessinsider.com - April 4 at 2:16 PMStoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Cantor Fitzgeraldmarketbeat.com - April 4 at 10:16 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent PullbackWayfair: Strengthening Fundamentals or Just a Short Squeeze? April 2, 2024 7:45 AMView Wayfair: Strengthening Fundamentals or Just a Short Squeeze? Can Netflix Stock Continue Into All-Time Highs After Earnings?April 18, 2024 7:32 AMView Can Netflix Stock Continue Into All-Time Highs After Earnings?PayPal’s User Decline Won’t Stop Its Double-Digit UpsideApril 16, 2024 9:08 AMView PayPal’s User Decline Won’t Stop Its Double-Digit UpsideTaylor Morrison: A Home Building Stock You Can Buy at a DiscountApril 11, 2024 7:00 AMView Taylor Morrison: A Home Building Stock You Can Buy at a DiscountAll Headlines Company DescriptionsArcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.AthenexNASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Enanta PharmaceuticalsNASDAQ:ENTAEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Stoke TherapeuticsNASDAQ:STOKStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.